Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Not only did I not know that longtime local brewery Novo Brazil had opened a new spot in the Mission Valley Mall, but I also ...